Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

koncentrat za raztopino za infundiranje - cisplatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

raztopina za injiciranje - cisplatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

koncentrat za raztopino za infundiranje - cisplatin

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck europe b.v. - avelumab - neuroendokrine tumorje - druga zdravila z delovanjem na novotvorbe agenti, monoklonalna protitelesa - zdravilo bavencio je indicirano za samostojno zdravljenje odraslih bolnikov z metastatskim karcinomom merkelove celice (mcc). bavencio v kombinaciji z axitinib je določen za prvo linijo za zdravljenje odraslih bolnikov z napredovalim karcinomom ledvičnih (rkc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastična sredstva - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinom, pljučni pljuč - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastična sredstva - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - oksaliplatin - koncentrat za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strides arcolab international limited - oksaliplatin - prašek za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

strides arcolab international limited - oksaliplatin - prašek za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin